ES2173948T3 - Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral. - Google Patents

Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.

Info

Publication number
ES2173948T3
ES2173948T3 ES95909917T ES95909917T ES2173948T3 ES 2173948 T3 ES2173948 T3 ES 2173948T3 ES 95909917 T ES95909917 T ES 95909917T ES 95909917 T ES95909917 T ES 95909917T ES 2173948 T3 ES2173948 T3 ES 2173948T3
Authority
ES
Spain
Prior art keywords
hydrocarbamide
didesoxi
inosine
blends
inhibition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95909917T
Other languages
English (en)
Inventor
Serge D Malley
Raul Jorge Vila
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of ES2173948T3 publication Critical patent/ES2173948T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN METODO Y COMPOSICION PARA INHIBIR LA EXPANSION DE UN RETROVIRUS COMO EL VIH DE UNA POBLACION CELULAR HUMANA, EN LA QUE EL RETROVIRUS, COMO EL VIH, SE ENCUENTRA PRESENTE. LA EXPANSION DEL RETROVIRUS SE INHIBE MEDIANTE EL TRATAMIENTO DE LAS CELULAS CON UNA MEZCLA DE COMBINACION SINERGISTICA DE UN DIDEOXINUCLEOSIDO, EXCLUYENDO AZT E HIDROXICARBAMIDA.
ES95909917T 1993-12-20 1994-12-20 Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral. Expired - Lifetime ES2173948T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/169,253 US5521161A (en) 1993-12-20 1993-12-20 Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Publications (1)

Publication Number Publication Date
ES2173948T3 true ES2173948T3 (es) 2002-11-01

Family

ID=22614846

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95909917T Expired - Lifetime ES2173948T3 (es) 1993-12-20 1994-12-20 Mezclas de 2',3'-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.

Country Status (13)

Country Link
US (2) US5521161A (es)
EP (1) EP0735890B1 (es)
AT (1) ATE216245T1 (es)
AU (1) AU1821295A (es)
CA (1) CA2179627C (es)
DE (1) DE69430440T2 (es)
DK (1) DK0735890T3 (es)
ES (1) ES2173948T3 (es)
OA (1) OA10721A (es)
PT (1) PT735890E (es)
TW (1) TW283645B (es)
WO (1) WO1995017899A2 (es)
ZA (1) ZA949219B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US6069252A (en) * 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
SE9003151D0 (sv) * 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
EP0610444B1 (en) 1991-10-31 2003-01-29 ELFORD, Howard L. Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases
EP0706387B1 (en) * 1993-05-21 2004-08-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
US6677310B1 (en) * 1999-04-21 2004-01-13 Nabi Ring-expanded nucleosides and nucleotides
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide
US6093702A (en) * 1993-12-20 2000-07-25 The United States Of America As Represented By The Department Of Health And Human Services Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread
HUT76331A (en) * 1994-07-15 1997-08-28 Lepetit Spa Dinucleoside-5',5'-pyrophosphates
US6391859B1 (en) 1995-01-27 2002-05-21 Emory University [5-Carboxamido or 5-fluoro]-[2′,3′-unsaturated or 3′-modified]-pyrimidine nucleosides
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869493A (en) 1996-02-16 1999-02-09 Medivir Ab Acyclic nucleoside derivatives
US6511848B2 (en) * 1996-04-17 2003-01-28 Winfried Albert Process for producing and multiplying lymphocytes
US5719132A (en) * 1996-06-27 1998-02-17 Bristol-Myers Squibb Company Compositions and methods of treating HIV with d4T, 5-fluorouracil/tegafur, and uracil
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6218386B1 (en) 1996-11-08 2001-04-17 Dupont Pharmaceuticals A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor
US5932570A (en) * 1996-11-08 1999-08-03 Dupont Pharmaceuticals Company 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors
US6686462B2 (en) * 1997-02-28 2004-02-03 The Regents Of The University Of California Antiviral compounds and methods of administration
US6114312A (en) * 1997-03-07 2000-09-05 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus by combined use of hydroxyurea, a nucleoside analog, and a protease inhibitor
EP0971715A1 (en) * 1997-03-20 2000-01-19 Compagnie De Developpement Aguettant Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread
US6140368A (en) * 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
JP2001512830A (ja) * 1997-08-08 2001-08-28 ニューバイオティックス インコーポレイテッド 生物療法耐性および化学療法耐性を克服するための方法および組成物
US20020022034A1 (en) * 1997-09-15 2002-02-21 Julianna Lisziewicz Therapeutic DNA vaccination
KR100286373B1 (ko) * 1997-10-17 2001-04-16 윤종용 적외선 데이터 통신을 위한 휴대용 컴퓨터
US7462605B2 (en) * 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
IL137164A0 (en) 1998-01-23 2001-07-24 Newbiotics Inc Enzyme catalyzed therapeutic agents
US6015796A (en) * 1998-03-11 2000-01-18 Zeria Pharmaceutical Co., Ltd. Method for treating AIDS
US6251874B1 (en) * 1998-03-26 2001-06-26 Research Institute For Genetic And Human Therapy (R.I.G.H.T.) Method of inhibiting human immunodeficiency virus using hydroxurea and a reverse transcriptase inhibitor in vivo
CA2335617C (en) * 1998-06-24 2009-12-15 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
WO2000045844A1 (en) * 1999-02-03 2000-08-10 Franco Lori Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
US6020325A (en) * 1999-03-09 2000-02-01 Zeria Pharmaceutical Co., Ltd. Method for inhibiting replication of HIV
BR0012676A (pt) 1999-07-22 2003-07-01 Newbiotics Inc Métodos para tratamento de tumores resistentes a terapia
US6683061B1 (en) * 1999-07-22 2004-01-27 Newbiotics, Inc. Enzyme catalyzed therapeutic activation
NL1012825C2 (nl) * 1999-08-13 2001-02-23 Faculteit Geneeskunde Universi Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).
US6479466B1 (en) 1999-08-13 2002-11-12 University Of Maryland Compositions for treating viral infections, and methods therefor
AU2002241911B9 (en) * 2001-01-19 2007-01-25 Celmed Oncology (Usa), Inc. Methods to treat autoimmune and inflammatory conditions
WO2003100009A2 (en) * 2002-05-23 2003-12-04 Biocryst Pharmaceuticals, Inc. Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
NZ216172A (en) * 1985-05-15 1989-08-29 Wellcome Found Nucleosides and pharmaceutical compositions
WO1987001284A1 (en) * 1985-08-26 1987-03-12 United States Of America, Represented By The Unite Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine
US5110600A (en) * 1988-01-25 1992-05-05 The Regents Of The University Of California Method of treating viral infections with amino acid analogs
US5026687A (en) * 1990-01-03 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
US5300059A (en) * 1991-11-19 1994-04-05 Hydro Slip Technologies Inc. Bloodbag and method of making same
EP0706387B1 (en) * 1993-05-21 2004-08-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
US5521161A (en) * 1993-12-20 1996-05-28 Compagnie De Developpment Aguettant S.A. Method of treating HIV in humans by administration of ddI and hydroxycarbamide

Also Published As

Publication number Publication date
US5521161A (en) 1996-05-28
DK0735890T3 (da) 2002-08-05
EP0735890B1 (en) 2002-04-17
CA2179627C (en) 2000-02-22
DE69430440D1 (de) 2002-05-23
US5736527A (en) 1998-04-07
OA10721A (en) 2002-12-09
DE69430440T2 (de) 2002-11-14
ZA949219B (en) 1995-08-01
WO1995017899A2 (en) 1995-07-06
TW283645B (es) 1996-08-21
WO1995017899A3 (en) 1995-08-10
EP0735890A1 (en) 1996-10-09
PT735890E (pt) 2002-09-30
ATE216245T1 (de) 2002-05-15
AU1821295A (en) 1995-07-17
CA2179627A1 (en) 1995-07-06

Similar Documents

Publication Publication Date Title
ES2173948T3 (es) Mezclas de 2&#39;,3&#39;-didesoxi-inosina e hidrocarbamida para la inhibicion de la propagacion retroviral.
NO953093D0 (no) Forbindelser med både sterk kalsiumantagonist- og antioksidantvirkning, samt anvendelse derav som cellebeskyttende midler
BR9916879A (pt) Composição e método para tratamento do câncer utilizando óleos essenciais vegetais naturais
MX9700237A (es) Combinaciones inhibidoras de proteasa retroviral.
DE3587434D1 (de) Antivirale pharmazeutische zusammensetzungen und ihrer verwendung.
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
TR200002191T2 (tr) Potasyum kanal önleyicileri
BR9811099A (pt) Inibidores de urocinase
PT1039912E (pt) Agentes angiostaticos e composicoes para tratar glaucoma glc1a
DE69811062D1 (de) Polyaromatische antivirale zusammensetzungen
MY111260A (en) Pharmaceutical composition for the treatment of nicotine dependence
ATE206916T1 (de) Zusammensetzungen zur erhöhung der konzentration und/oder beweglichkeit von samenzellen in menschen
BR9811298A (pt) Uso de um composto de vanádio fisiologicamente aceitável
BR9611642A (pt) Compostos composição farmacéutica e processo para a preparação de compostos
BR9814284A (pt) Composições e métodos para regulação de fagocitose e expressão de icam-1
ATE158947T1 (de) Hautregenerierende kosmetische zusammensetzung
ES2036174T3 (es) Un procedimiento para la preparacion de una combinacion broncodilatadora de prazosin-pirbuterol.
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
BR9913846A (pt) Antagonista receptor de quemocina e ciclosporina em terapia combinada
AU6835096A (en) A new family of compounds having anti-inflammatory and anti-viral activity and compositions of these, alone and in combination with reverse transcriptase inhibitors, for inhibiting, preventing or eliminating viral replication and methods of using same
EA199700032A1 (ru) Дезинфицирующий состав &#34;велтолен&#34;
ES2065855B1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
MX9701606A (es) Terapia de combinacion para evitar la perdida osea-progesterona y agonistas de estrogeno.
BR9812002A (pt) Compostos com efeito antiprimeiro-passe
ES2162022T3 (es) Derivados de tiol con actividad inhibidora de la metalopeptidasa.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 735890

Country of ref document: ES